Immunotherapy Moves to the Front Line: What Opdivo's Hodgkin Lymphoma Approval Means for Blood Cancer Treatment

There is a particular kind of regulatory milestone that does more than add a new indication to a drug label. It reorders the clinical hierarchy of an entire disease. The FDA's approval of nivolumab, sold by Bristol Myers Squibb as Opdivo, in combination with standard chemotherapy for previously untreated Stage III and IV classical Hodgkin lymphoma on March 20, 2026 is that kind of milestone.

What the Trial Actually Showed

The approval rests on the SWOG 1826 study, a randomized, multicenter Phase 3 trial that enrolled 994 patients aged 12 and older with previously untreated Stage III or IV classical Hodgkin lymphoma. The trial compared nivolumab plus the AVD chemotherapy regimen against brentuximab vedotin plus AVD. The nivolumab arm demonstrated a 58% reduction in the risk of disease progression or death, with a hazard ratio of 0.42 and a p-value below 0.0001. After a median follow-up of 36.7 months, deaths occurred in 1.8% of patients receiving nivolumab plus AVD, compared to 3.4% in the brentuximab vedotin arm.

The study was sponsored by the National Cancer Institute and conducted through the SWOG Cancer Research Network in collaboration with the Children's Oncology Group, making it one of the largest Hodgkin lymphoma trials ever conducted in the NCI National Clinical Trials Network.

The Disease and Why This Matters

Classical Hodgkin lymphoma is one of the most curable cancers in medicine, with five-year survival rates exceeding 85% for all stages combined. But advanced-stage disease carries a substantially higher risk of relapse, and relapse typically requires salvage chemotherapy, autologous stem cell transplantation, and additional lines of therapy. Hodgkin lymphoma is the most common cancer diagnosed in adolescents between the ages of 15 and 19. The patients who benefit from better frontline therapy are often people with decades of life ahead of them.

The significance of the SWOG 1826 result is therefore not just statistical. A more effective frontline regimen could reduce the proportion of patients who relapse and require intensive salvage therapies. If fewer patients need autologous stem cell transplantation because their disease was better controlled from the outset, the cumulative treatment burden across a lifetime is meaningfully reduced.

The Competitive Context and What It Displaces

The approval simultaneously converted two earlier accelerated approvals for nivolumab in relapsed or refractory classical Hodgkin lymphoma into traditional approvals, resolving a decade-long regulatory arc that began when the drug first demonstrated activity in heavily pretreated patients in 2016 and 2017.

The drug it displaced as the standard of care comparator in SWOG 1826 is brentuximab vedotin plus AVD, a regimen that itself represented a significant advance over older ABVD chemotherapy when it was approved for frontline use in 2018. Pfizer, which acquired brentuximab vedotin through its purchase of Seagen, now faces a more complicated commercial picture. On the same day as the U.S. approval, the European Commission approved nivolumab in combination with brentuximab vedotin for children, adolescents, and young adults up to age 30 with relapsed or refractory classical Hodgkin lymphoma after one prior line of therapy.

What Checkpoint Inhibitors Have Learned From Hodgkin Lymphoma

Classical Hodgkin lymphoma is characterized by Reed-Sternberg cells that express unusually high levels of PD-L1, the ligand that suppresses T-cell activity through the PD-1 pathway. The disease is, in a biological sense, almost designed to respond to PD-1 blockade. The early single-agent response rates that nivolumab and pembrolizumab demonstrated in relapsed Hodgkin lymphoma in the mid-2010s were among the highest ever seen with checkpoint inhibitors in any tumor type.

The SWOG 1826 result completes a logical arc. If PD-1 blockade works so well in relapsed disease, the question was always whether it could work even better when deployed earlier, before the immune system has been exhausted by multiple lines of chemotherapy. The answer, it turns out, is yes, and the magnitude of the benefit in a frontline setting against a strong comparator is larger than many observers anticipated.

The Broader Implications for Immuno-Oncology

The Hodgkin lymphoma approval arrives at a moment when the checkpoint inhibitor field is navigating a more complex landscape than it occupied five years ago. Hodgkin lymphoma represents a disease where the existing treatments already work well for most patients, and where the challenge is not achieving response but achieving durable remission with the least possible long-term harm. The SWOG 1826 data suggest that nivolumab plus AVD can deliver better disease control than the previous standard of care while maintaining a manageable safety profile. Serious adverse reactions occurred in 39% of patients in the nivolumab arm, and immune-mediated adverse reactions occurred in 9%, with Grade 3 to 4 events in 2.7%.

For Bristol Myers Squibb, the approval extends the commercial and scientific relevance of a franchise that has been under pressure from newer entrants and from the expiration of key patents. The Hodgkin lymphoma indication adds a high-profile first-line approval in a disease with strong clinical visibility and a patient population that tends to be young, engaged, and vocal about treatment options.

The deeper significance of the SWOG 1826 result is what it says about the direction of travel in blood cancer treatment. Immunotherapy has been slower to establish itself in hematologic malignancies than in solid tumors, with the notable exception of Hodgkin lymphoma itself. The first-line approval of nivolumab in advanced-stage disease is a reminder that the most biologically receptive tumors will continue to yield the most compelling clinical results, and that the work of identifying those tumors and matching them to the right immune interventions is far from finished.